Page 1318 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

References 3

of a Canadian collaborative study. Investigators of the 77. Kokame K, Matsumoto M, Soejima K, et al. Mutations and com-
Canadian Pediatric Kidney Disease Research Center. J Pediatr. mon polymorphisms in ADAMTS13 gene responsible for von
1998;132(5):777-782. Willebrand factor-cleaving protease activity. Proc Natl Acad Sci
60. Frank C, Werber D, Cramer JP, et al. Epidemic profile of U S A. 2002;99(18):11902-11907.
Shiga-toxin-producing Escherichia coli O104:H4 outbreak in 78. Pimanda JE, Maekawa A, Wind T, Paxton J, Chesterman CN,
Germany. N Engl J Med. 2011;365(19):1771-1780. Hogg PJ. Congenital thrombotic thrombocytopenic purpura
61. Lorenzen JM, Menne J, Schmidt BM, et al. Circulating in association with a mutation in the second CUB domain of
microRNAs in Patients with Shiga-Toxin-Producing E. coli ADAMTS13. Blood. 2004;103(2):627-629.
O104:H4 Induced Hemolytic Uremic Syndrome. PLoS One. 79. Uchida T, Wada H, Mizutani M, et al. Identification of
2012;7(10):e47215. novel mutations in ADAMTS13 in an adult patient with
62. Menne J, Nitschke M, Stingele R, et al. Validation of treatment congenital thrombotic thrombocytopenic purpura. Blood.
strategies for enterohaemorrhagic Escherichia coli O104:H4 2004;104(7):2081-2083.
induced haemolytic uraemic syndrome: case-control study. 80. Schneppenheim R, Kremer Hovinga JA, Becker T, et al. A com-
Bmj. 2012;345:e4565. mon origin of the 4143insA ADAMTS13 mutation. Thromb
63. Zipfel PF, Neumann HP, Jozsi M. Genetic screening in haemolytic Haemost. 2006;96(1):3-6.
uraemic syndrome. Curr Opin Nephrol Hypertens. 2003;12(6): 81. Lotta LA, Garagiola I, Palla R, Cairo A, Peyvandi F. ADAMTS13
653-657. mutations and polymorphisms in congenital thrombotic throm-
64. Kavanagh D, Goodship T. Genetics and complement in atypical bocytopenic purpura. Hum Mutat. 2010;31(1):11-19.
HUS. Pediatr Nephrol. 2010;25(12):2431-2442. 82. Lotta LA, Wu HM, MacKie IJ, et al. Residual plasmatic
65. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. activity of ADAMTS13 is correlated with phenotype severity
N Engl J Med. 2009;361(17):1676-1687. in congenital thrombotic thrombocytopenic purpura. Blood.
2012;120(2):440-448.
66. Baehr G, Klemperer P, Schifrin A. An acute febriel aenmia
and thrombocytopenic purpura with diffuse platelet throm- 83. Meyer S, Jin S, Cao W, Zheng XL, Lammle B, Kremer Hovinga
bosis of capillaries and arterioles. Trans Assoc Am Physicians. J. Characterization of five homozygous ADAMTS13 mutations
1936;51:43. in hereditary thrombotic thrombocytopenic purpura-towards a
phenotype-genotype correlation? Blood. 2008;112(11):108.
67. Hosler GA, Cusumano AM, Hutchins GM. Thrombotic throm- 84. Tsai HM, Lian EC. Antibodies to von Willebrand factor-
bocytopenic purpura and hemolytic uremic syndrome are cleaving protease in acute thrombotic thrombocytopenic pur-
distinct pathologic entities. A review of 56 autopsy cases. Arch pura. N Engl J Med. 1998;339(22):1585-1594.
Pathol Lab Med. 2003;127(7):834-839.
68. Asada Y, Sumiyoshi A, Hayashi T, Suzumiya J, Kaketani K. 85. Luken BM, Turenhout EA, Hulstein JJ, Van Mourik JA, Fijnheer R,
Voorberg J. The spacer domain of ADAMTS13 contains a major
Immunohistochemistry of vascular lesion in thrombotic throm- binding site for antibodies in patients with thrombotic thrombo-
bocytopenic purpura, with special reference to factor VIII cytopenic purpura. Thromb Haemost. 2005;93(2):267-274.
related antigen. Thromb Res. 1985;38(5):469-479.
69. Tsai HM, Chandler WL, Sarode R, et al. von Willebrand factor 86. Luken BM, Kaijen PH, Turenhout EA, et al. Multiple B-cell
clones producing antibodies directed to the spacer and disinte-
and von Willebrand factor-cleaving metalloprotease activity grin/thrombospondin type-1 repeat 1 (TSP1) of ADAMTS13 in
in Escherichia coli O157:H7-associated hemolytic uremic syn- a patient with acquired thrombotic thrombocytopenic purpura.
drome. Pediatr Res. 2001;49(5):653-659. J Thromb Haemost. 2006;4(11):2355-2364.
70. Tsai HM. Pathophysiology of thrombotic thrombocytopenic 87. Luken BM, Turenhout EA, Kaijen PH, et al. Amino acid regions
purpura. Int J Hematol. 2010;91(1):1-19. 572-579 and 657-666 of the spacer domain of ADAMTS13
71. Moake JL, Rudy CK, Troll JH, et al. Unusually large plasma provide a common antigenic core required for binding of
factor VIII:von Willebrand factor multimers in chronic relaps- antibodies in patients with acquired TTP. Thromb Haemost.
ing thrombotic thrombocytopenic purpura. N Engl J Med. 2006;96(3):295-301.
1982;307(23):1432-1435. 88. Zheng XL, Wu HM, Shang D, et al. Multiple domains of
72. Dong JF, Moake JL, Nolasco L, et al. ADAMTS13 rapidly cleaves ADAMTS13 are targeted by autoantibodies against ADAMTS13
newly secreted ultralarge von Willebrand factor multimers in patients with acquired idiopathic thrombotic thrombocyto-
on the endothelial surface under flowing conditions. Blood. penic purpura. Haematologica. 2010;95(9):1555-1562.
2002;100(12):4033-4039. 89. Ai J, Smith P, Wang S, Zhang P, Zheng XL. The proximal
73. Dong JF, Moake JL, Bernardo A, et al. ADAMTS13 carboxyl-terminal domains of ADAMTS13 determine substrate
metalloprotease interacts with the endothelial cell-derived specificity and are all required for cleavage of von Willebrand
ultra-large von Willebrand factor. J Biol Chem. 2003;278(32): factor. J Biol Chem. 2005;280(33):29428-29434.
29633-29639. 90. Gao W, Anderson PJ, Majerus EM, Tuley EA, Sadler JE. Exosite
74. Dong JF. Cleavage of ultra-large von Willebrand factor by interactions contribute to tension-induced cleavage of von
ADAMTS13 under flow conditions. J Thromb Haemost. Willebrand factor by the antithrombotic ADAMTS13 metallo-
2005;3(8):1710-1716. protease. Proc Natl Acad Sci U S A. 2006;103(50):19099-19104.
75. Tsai HM. Shear stress and von Willebrand factor in health and 91. Gao W, Anderson PJ, Sadler JE. Extensive contacts between
disease. Semin Thromb Hemost. 2003;29(5):479-488. ADAMTS13 exosites and von Willebrand factor domain A2
76. Vincentelli A, Susen S, Le Tourneau T, et al. Acquired von contribute to substrate specificity. Blood. 2008;112(5):1713-1719.
Willebrand syndrome in aortic stenosis. N Engl J Med. 92. Jin SY, Skipwith CG, Zheng XL. Amino acid residues Arg(659),
2003;349(4):343-349. Arg(660), and Tyr(661) in the spacer domain of ADAMTS13

Section07-O-ref.indd 3 1/21/2015 11:26:48 AM